The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma†
Open accessAbstract
UNLABELLED: This is a phase II clinical trial investigating the safety and efficacy of intravenous vaccination with mature autologous dendritic cells (DCs) pulsed ex vivo with a liver tumor cell line lysate (HepG2) in patients with advanced hepatocellular carcinoma (HCC). HCC is an attractive target for immunotherapy as evidenced by an active recruitment of tumor-infiltrating lymphocytes that are capable of lysing autologous tumor cells in ex vivo studies. DCs are the most potent antigen-presenting cells, with the capacity to take up, process, and present tumor antigens to T cells and stimulate an immune response, thus providing a rational platform for vaccine development. Thirty-five patients with advanced HCC and not suitable for radical or loco-regional therapies received a maximum of six DC vaccinations each at 3-week intervals. In total, 134 DC infusions were administered with no significant toxicity and no evidence of autoimmunity. Twenty-five patients who received at least three vaccine infusions were assessed clinically for response. The radiologically determined disease control rate (combined partial response and stable disease >or=3 months) was 28%. In 17 patients the baseline serum alpha-fetoprotein (AFP) was >or= 1,000 ng/mL; in four of these patients, it fell to <30% of baseline following vaccination. In one patient there was a radiological partial response associated with a fall in AFP to <10% of baseline. Immune responses were assessed using an ELIspot assay of interferon-gamma (IFN-gamma) release. In several cases there was induction of T cell responses to the vaccine and/or AFP following vaccination. CONCLUSION: Autologous DC vaccination in patients with HCC is safe and well tolerated with evidence of antitumor efficacy assessed radiologically and serologically, with generation of antigen-specific immune responses in some cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3894 · Cited by 625
Chemoembolization for hepatocellular carcinoma
Bruix, J., Sala, M., & Llovet, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.032 · Cited by 569
Dhodapkar, M. V., & Steinman, R. M. (2002) · Blood · doi:10.1182/blood.v100.1.174 · Cited by 363
Manipulating dendritic cell biology for the active immunotherapy of cancer
O'Neill, D. W., Adams, S., & Bhardwaj, N. (2004) · Blood · doi:10.1182/blood-2003-12-4392 · Cited by 339
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Frielink, C., Toonen, L. W. J., Boerman, O. C., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603341 · Cited by 296
HOLTL, L., RIESER, C., PAPESH, C., RAMONER, R., HEROLD, M., KLOCKER, H., RADMAYR, C., STENZL, A., BARTSCH, G., & THURNHER, M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61767-1 · Cited by 244
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Raoul, J., Zeuzem, S., Poulin-Costello, M., Moscovici, M., Voliotis, D., & Bruix, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba1 · Cited by 237
Butterfield, L. H., Ribas, A., Dissette, V. B., Lee, Y., Yang, J. Q., De la Rocha, P., Duran, S. D., Hernandez, J., Seja, E., Potter, D. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2856 · Cited by 232
Dendritic cells: a journey from laboratory to clinic
Cerundolo, V., Hermans, I. F., & Salio, M. (2004) · Nature Immunology · doi:10.1038/ni0104-7 · Cited by 194
Chi, K.-H., Liu, S.-J., Li, C.-P., Kuo, H.-P., Wang, Y.-S., Chao, Y., & Hsieh, S.-L. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000154248.74383.5e · Cited by 187
Lee, W.-C., Wang, H.-C., Hung, C.-F., Huang, P.-F., Lia, C.-R., & Chen, M.-F. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171291.72039.e2 · Cited by 185
Wissniowski, T. T., Hänsler, J., Neureiter, D., Frieser, M., Schaber, S., Esslinger, B., Voll, R. E., Strobel, D. D., Hahn, E. G., Schuppan, D., et al. (2003) · PubMed · Cited by 181
Butterfield, L. H., Ribas, A., Meng, W. S., Dissette, V. B., Amarnani, S. N., Vu, H. T., Seja, E., Todd, K., Glaspy, J. A., McBride, W. H., et al. (2003) · PubMed · Cited by 162
Yoong, K. F., Afford, S. C., Jones, R. L., AUJLA, P., Qin, S., Price, K., Hübscher, S. G., & Adams, D. (1999) · Hepatology · doi:10.1002/hep.510300147 · Cited by 127
Self-citationIwashita, Y., Tahara, K., Goto, S., Sasaki, A., Kai, S., Seike, M., Chen, C., Kawano, K., & Kitano, S. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0360-9 · Cited by 124
Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8
Feijoó, E., Alfaro, C., Mazzolini, G. D., Serra, P., Peñuelas, I., Arina, A., Huarte, E., Tirapu, I., Palencia, B., Murillo, O., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21046 · Cited by 122
Expression of cancer-testis genes in human hepatocellular carcinomas.
Luo, G., Huang, S., Xie, X., Stockert, E., Chen, Y., Kubuschok, B., & Pfreundschuh, M. G. (2002) · PubMed · Cited by 78
Liu, Y., Daley, S., Evdokimova, V. N., Zdobinski, D. D., Potter, D. M., & Butterfield, L. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.712 · Cited by 67
Butterfield, L. H., Ribas, A., Potter, D. M., & Economou, J. S. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0337-9 · Cited by 65
Gonzalez-Carmona, M. A., Lukacs‐Kornek, V., Timmerman, A., Shabani, S., Kornek, M., Vogt, A., Yildiz, Y., Sievers, E., Schmidt‐Wolf, I. G. H., Caselmann, W. H., et al. (2008) · Hepatology · doi:10.1002/hep.22296 · Cited by 64
Schumacher, L., Ribas, A., Dissette, V. B., McBride, W. H., Mukherji, B., Economou, J. S., & Butterfield, L. H. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200405000-00003 · Cited by 60
AFP-specific CD4+ Helper T-cell Responses in Healthy Donors and HCC Patients
Evdokimova, V. N., Liu, Y., Potter, D. M., & Butterfield, L. H. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802fd8e2 · Cited by 52
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 52
Nakamoto, Y., Mizukoshi, E., Tsuji, H., Sakai, Y., Kitahara, M., Kazumori, A. R. A. I., Yamashita, T., Yokoyama, K., Mukaida, N., Matsushima, K., et al. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03290.x · Cited by 46
Sellge, G., Lorentz, A., Gebhardt, T., Levi‐Schaffer, F., Bektas, H., Manns, M. P., Schuppan, D., & Bischoff, S. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.260 · Cited by 41
Recent advances in immunotherapy for hepatocellular cancer
Butterfield, L. H. (2006) · Swiss Medical Weekly · doi:10.57187/smw.2007.11077 · Cited by 37
Chen, Y., Man, K., Ling, G. S., Chen, Y., Sun, B., Cheng, Q., Wong, O. H., Lo, C.-K., Ng, I. O., Chan, L. C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.6009 · Cited by 35
The role of the immune system in the control of hepatocellular carcinoma
O’Beirne, J. P., & Harrison, P. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200412000-00003 · Cited by 29
Friedl, J., Stift, A., Paolini, P., Roth, E., Steger, G. G., Mader, R. M., Jakesz, R., & Gnant, M. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.477 · Cited by 27
Production and Properties of Large Numbers of Dendritic Cells from Human Blood
Schuler, G., Brang, D., & Romani, N. (1995) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1971-3_9 · Cited by 19
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Metadata
- Authors
- Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H.
- Venue
- Hepatology
- Published
- 2009-01
- Volume
- 49
- Issue
- 1
- Pages
- 124-132
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1990459651
- Cited by
- 286
- References
- 32
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.